Druckenmiller owns it, and its cancer blood test is growing fast. But after this run, I’m waiting for the correction. Here’s my entry.
NTRA crushing it though
It’s a good company, although at current prices it’s expensive. Maybe in a correction, if the opportunity arises, it wouldn’t be a bad option.
Agree,
NTRA crushing it though
It’s a good company, although at current prices it’s expensive. Maybe in a correction, if the opportunity arises, it wouldn’t be a bad option.
Agree,